Fundz Deep Dive
Everything you need to win Adaptin Bio — in one platform.
Who to reach, what to say, and why now on Adaptin Bio — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Adaptin Bio — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Adaptin Bio, Inc. Completes Strategic Partnership for APTN-101 Clinical Trial Funding
Apr 07, 2025•about 1 year ago
Contract Type
partnership
CharlotteBiotechnologyHealth CareTherapeuticsDescription
Adaptin Bio, Inc. has successfully completed a strategic partnership through a reverse merger and private placement, raising approximately $7.7 million. The funding is expected to support the first clinical trial of APTN-101 for the treatment of glioblastoma, as well as the development of other early-stage drug product candidates for rare and unmet needs.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months